Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.5
2.3
Journals
JCDD
Special Issues
Interventional Diagnostics and Treatment of Coronary Artery Disease
share announcement

Interventional Diagnostics and Treatment of Coronary Artery Disease

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Acquired Cardiovascular Disease".

Deadline for manuscript submissions: 31 August 2026 | Viewed by 1071

Special Issue Editor

Prof. Dr. Tomasz Rakowski

E-Mail Website
Guest Editor
1. 2nd Department of Cardiology, Institute of Cardiology, Jagiellonian University Medical College, 30-688 Kraków, Poland
2. Department of Cardiology and Cardiovascular Interventions, University Hospital, 30-688 Kraków, Poland
Interests: coronary artery disease; acute coronary syndromes; percutaneous coronary interventions; antiplatelet therapy; cardiac imaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Coronary artery disease is still the leading cause of death worldwide. Numerous research studies are conducted to improve diagnostics and treatment strategies and, finally, patients’ clinical outcomes. The landscape of invasive and non-invasive diagnostics, pharmacotherapy, and interventional (percutaneous and surgical) techniques has substantially changed, and rapid progress has been observed during recent years.

It is our pleasure to invite you to contribute to the Special Issue on “Interventional Diagnostics and Treatment of Coronary Artery Disease,” which is focused on several aspects of coronary artery disease in chronic and acute coronary syndrome patients. Authors are invited to submit original research studies, state-of-the-art reviews, short contributions, and case reports. This Special Issue is mostly focused on invasive and non-invasive coronary diagnostics, pharmacotherapy, coronary revascularization with percutaneous coronary interventions and surgical techniques, epidemiology, and outcome studies.

Prof. Dr. Tomasz Rakowski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • coronary artery disease
  • myocardial ischemia
  • myocardial viability
  • chronic coronary syndromes
  • acute coronary syndromes
  • MINOCA
  • INOCA
  • coronary revascularization
  • percutaneous coronary interventions
  • coronary artery surgical revascularization
  • coronary artery bypass grafting
  • cardiac imaging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

28 pages, 3472 KB  
Review
Is Aspirin Still Indispensable After PCI—Rethinking Dual Antiplatelet Therapy in Contemporary Practice
by Kartik Yadav, Sama Ehab Salah Ahmed, Mohamed Abdelgader, Roann Khalid, Murugapathy Veerasamy, Arka Das and Heerajnarain Bulluck
J. Cardiovasc. Dev. Dis. 2026, 13(5), 201; https://doi.org/10.3390/jcdd13050201 - 9 May 2026
Viewed by 778
Abstract
Aspirin has been the default backbone of antiplatelet therapy after percutaneous coronary intervention (PCI) for over two decades, anchored by landmark trials that established 12-month dual antiplatelet therapy (DAPT) as the standard of care. Three developments have prompted reassessment of this paradigm: the [...] Read more.
Aspirin has been the default backbone of antiplatelet therapy after percutaneous coronary intervention (PCI) for over two decades, anchored by landmark trials that established 12-month dual antiplatelet therapy (DAPT) as the standard of care. Three developments have prompted reassessment of this paradigm: the markedly lower thrombotic risk of contemporary drug-eluting stents, the greater potency and consistency of potent P2Y12 inhibitors (ticagrelor, prasugrel), and increasing recognition that major bleeding independently worsens outcomes after PCI. Recent randomised trials have systematically tested aspirin withdrawal at varying time points. Immediate aspirin-free strategies (NEO-MINDSET, STOPDAPT-3) demonstrated an early signal of excess ischaemic events in the ACS component of enrolled populations, suggesting that aspirin remains important during the earliest post-PCI period in ACS. One-month strategies (T-PASS, ULTIMATE-DAPT, TARGET-FIRST) and three-month strategies (TWILIGHT, TICO, DUAL-ACS) showed that transition to P2Y12 monotherapy after an initial DAPT period significantly reduces bleeding without increasing ischaemic events in selected populations. Beyond one year, long-term randomised trials including the HOST-EXAM 10-year follow-up (Lancet 2026) and the STOPDAPT-2 5-year landmark analysis (Circ Cardiovasc Interv 2026), together with study-level meta-analyses (PANTHER) and recent individual patient data meta-analyses, provide converging evidence that clopidogrel monotherapy outperforms aspirin for chronic secondary prevention without excess bleeding. The choice of P2Y12 agent is critical: clopidogrel monotherapy in ACS during the first post-procedural year carries excess thrombotic risk owing to CYP2C19 pharmacogenomic variability, whereas ticagrelor and prasugrel provide more reliable protection. This review synthesises the mechanistic rationale, trial evidence across all time points, special clinical contexts (oral anticoagulation, coronary artery bypass grafting, high bleeding risk), guideline evolution, and methodological considerations, providing a practical framework for individualising post-PCI antiplatelet therapy. Full article
(This article belongs to the Special Issue Interventional Diagnostics and Treatment of Coronary Artery Disease)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop